To evaluate the therapeutic efficacy of si3033 in vivo, we utilized a mouse model of vitiligo that is based on the adoptive transfer of autoreactive CD8+ T cells that target melanocyte-specific premelanosome protein (PMEL) of recipient mice36,37. This evidence concerns the gene CD8A and vitiligo.